RightEye Has “Breakthrough” in Its Vision for Parkinson’s Test

There could soon be an eye test to aid in the assessment of Parkinson’s disease. FDA has recently granted breakthrough device designation to a technology designed by RightEye that uses objective eye movement measurements to help detect the neurological disease. If the RightEye Vision System could gain a nod from FDA for detection, it would be a gamechanger because currently, no single test is capable of definitively diagnosing Parkinson's disease. Doctors instead rely on a variety of neurological examinations designed to confirm the clinical diagnosis, and misdiagnosis remains a continuing issue for the health community. "With this FDA Breakthrough Device Designation, RightEye has an opportunity to address a critical unmet need in the fight against Parkinson's Disease," Adam Gross, co-founder, and CEO at RightEye said in a release. "The annual cost of Parkinson's disease in America is estimated at approximately $52 billion. Earlier assessment, intervention, and more accurate diagnoses are anticipated to reduce these costs, while also improving patient outcomes and quality of life." The Bethesda, MD-based company’s Vision System has already earned some stripes from FDA. In 2018 the device received clearance from the federal agency for recording, viewing, and analyzing eye movements in support of identifying visual tracking impairment in patients. The data provided by this eye-tracking technology has also demon...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news

Related Links:

Medtronic obtained the European CE Mark for its Percept PC neurostimulator that uses smart feedback technology to deliver deep brain stimulation to treat Parkinson’s and other neurologic diseases. The so-called BrainSense technology powe...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Source Type: blogs
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by hypokinetic motor features; however, patients also display non-motor symptoms like sleep disorders. The standard treatment for PD is dopamine replacement with L-DOPA; however, symptoms including gait deficits and sleep disorders are unresponsive to L-DOPA. Notably, these symptoms have been linked to aberrant activity in the pedunculopontine nucleus (PPN). Of late, clinical trials involving PPN deep brain stimulation (DBS) have been employed to alleviate gait deficits. Although preclinical evidence implicating PPN cholinergic neurons in gait dys...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective therapeutic strategy for motor symptoms of Parkinson's disease (PD) when L-DOPA therapy induces disabling side effects. Classical inflammatory activation of glial cells is well established in PD, contributing to the progressive neurodegenerative state; however, the role of DBS in regulating the inflammatory response remains largely unknown. To understand the involvement of astrocytes in the mechanisms of action of DBS, we evaluated the effect of STN-DBS in regulating motor symptoms, astrocyte reactivity, and cytokine expression ...
Source: Cellular and Molecular Neurobiology - Category: Cytology Authors: Tags: Cell Mol Neurobiol Source Type: research
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPI) was approved in 2002 as a treatment option for Parkinson's disease (PD), although it had been in use since the 1980s. Since then, more than 160,000 patients worldwide have received DBS, and as the incidence of PD is rising sharply, the number of people with PD who have undergone DBS will also increase. Importantly, an additional effect of longevity (related in part to deployment of advanced treatments for PD [1]), the likelihood increases of encountering a co-occurrence of cancer in patients treated with DBS.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Correspondence Source Type: research
Condition:   Parkinson Disease Intervention:   Procedure: Directional and single ring STN-DBS on gait Sponsor:   University Hospital, Rouen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsIn this cohort, amantadine was used in 10% of patients. Its use increased during follow-up, despite the fact that one-third of patients who received amantadine at baseline stopped taking it. Amantadine prescription was mainly correlated with the presence of dyskinesia.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Condition:   Parkinson Disease Intervention:   Procedure: Directional and single ring STN-DBS on gait Sponsor:   University Hospital, Rouen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Vaz Cunha Deep brain stimulation (DBS) surgery is the gold standard therapeutic intervention in Parkinson’s disease (PD) with motor complications, notwithstanding drug therapy. In the intraoperative evaluation of DBS’s efficacy, neurologists impose a passive wrist flexion movement and qualitatively describe the perceived decrease in rigidity under different stimulation parameters and electrode positions. To tackle this subjectivity, we designed a wearable device to quantitatively evaluate the wrist rigidity changes during the neurosurgery procedure, supporting physicians in decision-making when s...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
Condition:   Parkinson Disease Intervention:   Device: Vercise DBS System Sponsors:   Jonathan Jagid;   Boston Scientific Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Carbidopa/Levodopa | Deep Brain Stimulation | Medical Devices | Neurology | Neuroscience | Parkinson's Disease | Study